Lingfang Xia

759 total citations
35 papers, 485 citations indexed

About

Lingfang Xia is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Lingfang Xia has authored 35 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Obstetrics and Gynecology, 14 papers in Reproductive Medicine and 13 papers in Oncology. Recurrent topics in Lingfang Xia's work include Endometrial and Cervical Cancer Treatments (14 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Lingfang Xia is often cited by papers focused on Endometrial and Cervical Cancer Treatments (14 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Lingfang Xia collaborates with scholars based in China and United States. Lingfang Xia's co-authors include Xiaohua Wu, Xingzhu Ju, Yong Wu, Hao Wen, Qinhao Guo, Xiaojun Chen, Jun Zhu, Guihao Ke, Xiaohua Wu and Jia Tang and has published in prestigious journals such as Nature Communications, Oncogene and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Lingfang Xia

34 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingfang Xia China 15 205 172 170 118 112 35 485
Gonzalo Giornelli Argentina 5 254 1.2× 110 0.6× 241 1.4× 84 0.7× 46 0.4× 8 421
Shari Thomas United States 4 143 0.7× 308 1.8× 58 0.3× 50 0.4× 96 0.9× 9 443
Peter Widschwendter Germany 12 86 0.4× 151 0.9× 54 0.3× 72 0.6× 45 0.4× 31 306
Jamie Magrill Canada 8 502 2.4× 86 0.5× 420 2.5× 133 1.1× 100 0.9× 13 720
Mitsutake Yano Japan 13 148 0.7× 154 0.9× 152 0.9× 174 1.5× 18 0.2× 54 455
Christopher McCann United Kingdom 11 80 0.4× 117 0.7× 136 0.8× 187 1.6× 33 0.3× 20 395
Jeroen Depreeuw Belgium 9 289 1.4× 116 0.7× 199 1.2× 129 1.1× 41 0.4× 13 491
Ting‐Tai Yen United States 10 165 0.8× 87 0.5× 140 0.8× 172 1.5× 22 0.2× 17 433
Eunice H. Rhee United States 5 105 0.5× 133 0.8× 146 0.9× 92 0.8× 13 0.1× 5 403
Giuseppa Maltese Italy 11 203 1.0× 115 0.7× 215 1.3× 65 0.6× 11 0.1× 25 394

Countries citing papers authored by Lingfang Xia

Since Specialization
Citations

This map shows the geographic impact of Lingfang Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingfang Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingfang Xia more than expected).

Fields of papers citing papers by Lingfang Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingfang Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingfang Xia. The network helps show where Lingfang Xia may publish in the future.

Co-authorship network of co-authors of Lingfang Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Lingfang Xia. A scholar is included among the top collaborators of Lingfang Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingfang Xia. Lingfang Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xia, Lingfang, et al.. (2025). m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways. Oncogene. 44(14). 968–982. 7 indexed citations
3.
Wu, Jiangchun, Yong Wu, Siyu Chen, et al.. (2024). PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway. Oncogene. 43(12). 866–883. 8 indexed citations
4.
Wu, Xiaohua, Lingfang Xia, Keqiang Zhang, et al.. (2024). Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer. Gynecologic Oncology. 190. S23–S24. 1 indexed citations
5.
Shao, Yang, Hui Li, Yong Wu, et al.. (2023). The feedback loop of AURKA/DDX5/TMEM147-AS1/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer. Cancer Letters. 565. 216241–216241. 14 indexed citations
6.
Xia, Lingfang, et al.. (2023). Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. Acta Obstetricia Et Gynecologica Scandinavica. 102(7). 950–959. 4 indexed citations
7.
Xia, Lingfang, Qi Zhou, Yunong Gao, et al.. (2022). A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nature Communications. 13(1). 7581–7581. 17 indexed citations
8.
Yang, Yufei, Lingfang Xia, Yong Wu, et al.. (2021). Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Communications. 41(6). 511–527. 42 indexed citations
9.
Wu, Yong, Qinhao Guo, Xingzhu Ju, et al.. (2021). HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway. Oncogene. 40(29). 4770–4782. 14 indexed citations
10.
Zhu, Jun, Chunyan Song, Zhong Zheng, et al.. (2021). Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial. Frontiers in Oncology. 11. 720343–720343. 13 indexed citations
11.
Han, Xiaotian, Ye-Chen Lu, Xiaoqi Li, et al.. (2021). Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia. Frontiers in Oncology. 11. 643986–643986. 10 indexed citations
12.
Zhang, Wei, Lingfang Xia, Xiaotian Han, et al.. (2021). Extraperitoneal laparoscopy for para-aortic lymphadenectomy in endometrial carcinoma staging: an approach with higher efficiency. World Journal of Surgical Oncology. 19(1). 323–323. 4 indexed citations
13.
14.
Gu, Bingxin, Lingfang Xia, Huijuan Ge, & Shuai Liu. (2020). Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study. Quantitative Imaging in Medicine and Surgery. 10(3). 743–753. 14 indexed citations
15.
Li, Xiaoqi, Lingfang Xia, Xiaojun Chen, Yi Fu, & Xiaohua Wu. (2020). Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: A retrospective analysis and review of the literature. Gynecologic Oncology. 158(2). 231–235. 19 indexed citations
16.
Guo, Qinhao, Jun Zhu, Yong Wu, et al.. (2020). Comparison of different lymph node staging systems in patients with node-positive cervical squamous cell carcinoma following radical surgery. Journal of Cancer. 11(24). 7339–7347. 13 indexed citations
17.
Liu, Shuai, Lingfang Xia, Ziyi Yang, et al.. (2020). The feasibility of 18F-FDG PET/CT for predicting pathologic risk status in early-stage uterine cervical squamous cancer. Cancer Imaging. 20(1). 63–63. 5 indexed citations
18.
Xia, Lingfang, Shuang Ye, Xuxia Shen, et al.. (2018). Primary leiomyosarcoma of the fallopian tube: Three case reports and review of the literature. Taiwanese Journal of Obstetrics and Gynecology. 57(3). 456–461. 2 indexed citations
19.
Li, Xiaoqi, Hao Wen, Xiaojun Chen, et al.. (2016). The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. Annals of Surgical Oncology. 23(9). 2953–2958. 23 indexed citations
20.
Xia, Lingfang, Duo Han, Wentao Yang, et al.. (2013). Primary Malignant Melanoma of the Vagina. International Journal of Gynecological Cancer. 24(1). 149–155. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gonzalo Giornelli Breakdown of academic impact, for papers by Shari Thomas Breakdown of academic impact, for papers by Peter Widschwendter Breakdown of academic impact, for papers by Jamie Magrill Breakdown of academic impact, for papers by Mitsutake Yano Breakdown of academic impact, for papers by Christopher McCann Breakdown of academic impact, for papers by Jeroen Depreeuw Breakdown of academic impact, for papers by Ting‐Tai Yen Breakdown of academic impact, for papers by Eunice H. Rhee Breakdown of academic impact, for papers by Giuseppa Maltese
Rankless by CCL
2026